Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Autologous Ex Vivo Expanded Tumor-Infiltrating Lymphocyte (TIL) Therapy With Lifileucel After Failure of PD-1 Blockade in Kidney Cancer.

NCT07925333 is registered in ClinicalTrials.gov with Beth Israel Deaconess Medical Center as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07925333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Autologous Ex Vivo Expanded Tumor-Infiltrating Lymphocyte (TIL) Therapy With Lifileucel After Failure of PD-1 Blockade in Kidney Cancer.
Lead sponsor
Beth Israel Deaconess Medical Center
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 26, 2027
Completion date
March 1, 2030
Enrollment
10 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

kidney cancers, renal cell carcinoma (kidney cancer)

Arms

As registered; 1 arm.

  • Lifileucel (LN-145) TIL regimen ExperimentalAldesleukin (IL-2), Cyclophosphamide, Fludarabine, Tumor Resection

    Participants undergo tumor resection for TIL manufacturing, then receive lymphodepleting cyclophosphamide and fludarabine, followed byLN-145/lifileucel infusion and IL-2 (aldesleukin), with scheduled post-treatment clinic visits and long-term follow-up

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Radiographic Objective Response Rate Participants will be followed thought out the course of the trial for 3 years

    HCC-centrally assessed Objective Response Rate per RECIST 1.1 of the efficacy evaluable population Primary analysis is performed on patients who receive TIL.

Lead sponsor's other trials

Beth Israel Deaconess Medical Center, most recent start first.

Similar trials

Same condition (Carcinoma, Renal Cell) and phase, most recent start first.